Clin Case Rep Int | Volume 7, Issue 1 | Research Article | Open Access
Musso M*, Tona G, Scalone R, Crescimanno A, Porretto F, Lanza M, Bonanno V, Zammit V, Abbene I, Polizzi V and Iannitto E
Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, La Maddalena, Italy
*Correspondance to: Maurizio MussoFulltext PDF
Chimeric Antigen Receptor (CAR) T cells therapy is the standard of care for refractory/recurring Non-Hodgkin B Cell Lymphoma (R/R NHL). Nowadays increasing experience on CAR-T therapy shows that early-onset toxicity (cytokine releasing syndrome and neurotoxicity) is manageable, shifting the attention to late-onset toxicities like cytopenia and infections. Grade ≥ 3 thrombocytopenia occurs in almost one third of patients and still represents an unmet clinical need. Thrombopoietin mimetic (TPOm) Romiplostim, thanks to the results in Aplastic Anemia (AA) and immune thrombocytopenia, is off-label-used in this setting. Our experience on 7 patients with grade ≥ 3 thrombocytopenia, over a cohort of 21 patients who undergone CAR-T therapy between January 2021 and December 2022, confirms that management with Romiplostim is efficient and feasible.
Musso M, Tona G, Scalone R, Crescimanno A, Porretto F, Lanza M, et al. Single Center Experience on Management of CAR-T Related Thrombocytopenia. Clin Case Rep Int. 2023; 7: 1476.